Peter C.C. Fong
A5056423529- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- DNA Repair Mechanisms
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Toxin Mechanisms and Immunotoxins
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Advancements in Semiconductor Devices and Circuit Design
- Renal and related cancers
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Bladder and Urothelial Cancer Treatments
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Epigenetics and DNA Methylation
- Multiple Myeloma Research and Treatments
- Colorectal Cancer Treatments and Studies
University of Auckland
2012-2025
Auckland City Hospital
2016-2025
Leiden University Medical Center
2023
Auckland District Health Board
2014-2021
Peter MacCallum Cancer Centre
2021
Comprehensive Cancer Center Erlangen
2020
Universitätsklinikum Erlangen
2020
Royal Marsden NHS Foundation Trust
2005-2014
Institute of Cancer Research
2006-2014
Royal Marsden Hospital
2006-2014
The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment cancers with specific DNA-repair defects, including those arising in carriers BRCA1 or BRCA2 mutation. We conducted clinical evaluation humans olaparib (AZD2281), novel, potent, orally active PARP inhibitor.This was phase 1 trial that included analysis pharmacokinetic and pharmacodynamic characteristics olaparib. Selection aimed at having study...
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers whom cells have defective homologous recombination (HR) DNA repair. Platinum-based chemotherapy responses correlate with HR repair capacity. Olaparib is potent, oral PARP that well tolerated, antitumor activity carriers. Patients and Methods BRCA1/2-mutated ovarian cancer were treated olaparib within...
The principal objective of this trial was to evaluate the antitumor activity abiraterone acetate, an oral, specific, irreversible inhibitor CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC).In multicenter, two-stage, phase II study, acetate 1,000 mg administered once daily continuously. primary end point achievement a prostate-specific antigen (PSA) decline > or = 50% at least seven 35 patients. Per attained design, more than could be enrolled if met....
There is an unmet need for therapeutic options that prolong survival patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) biomarker-unselected, previously treated mCRPC.
Abstract Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives growth of prostate cancer cells, and poly(ADP-ribose) polymerase. This association provides a rationale for their co-inhibition treatment metastatic castration-resistant (mCRPC), area unmet medical need. The phase 3 TALAPRO-2 study investigated combining polymerase inhibitor talazoparib with enzalutamide versus alone as first-line mCRPC. Patients were prospectively assessed tumor...
LBA17 Background: TALAPRO-2 (NCT03395197) is the first phase 3 study to combine poly(ADP-ribose) polymerase inhibitor TALA with androgen receptor ENZA. Pts unselected for genetic alterations in DNA damage repair pathways, directly or indirectly involved homologous recombination (HRR), received either + ENZA PBO as 1L treatment mCRPC. Methods: randomized 1:1 0.5 mg (all pts 160 daily) were stratified by prior abiraterone docetaxel castration-sensitive PC and HRR gene alteration status. Key...
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.
LBA18 Background: The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs placebo (PBO) as 1L treatment in pts with mCRPC unselected homologous recombination repair (HRR) gene alterations (all-comers; cohort 1). Here we report final OS data, a descriptive update of rPFS, and extended safety follow-up 1. Methods: In 1, were randomized 1:1 to 160 mg either 0.5 (0.35 if moderate renal impairment) or PBO once daily...
Abstract Purpose: To detect insulin-like growth factor-IR (IGF-IR) on circulating tumor cells (CTC) as a biomarker in the clinical development of monoclonal human antibody, CP-751,871, targeting IGF-IR. Experimental Design: An automated sample preparation and analysis system for enumerating CTCs (CellTracks) was adapted detecting IGF-IR–positive with diagnostic antibody different IGF-IR epitope to CP-751,871. This assay used three phase I trials CP-751,871 single agent or chemotherapy...
Constitutive activation of ERK1/2 occurs in various cancers, and its reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors may overcome the limitations inhibitor blockade. The dual SCH772984 has shown promising preclinical activity across BRAFV600/RAS-mutant cancer cell lines human xenografts.We have developed an orally bioavailable inhibitor, MK-8353; conducted studies demonstrate activity, pharmacodynamic endpoints, dosing, schedule; completed study...
Journal Article Legislative Bargaining with Reconsideration Get access Daniel Diermeier, Diermeier Search for other works by this author on: Oxford Academic Google Scholar Pohan Fong The Quarterly of Economics, Volume 126, Issue 2, May 2011, Pages 947–985, https://doi.org/10.1093/qje/qjr016 Published: 01 2011
Abstract Mendelian-like inheritance of germline DNA methylation in cancer susceptibility genes has been previously reported. We aimed to scan the genome for heritable marks associated with breast by studying 25 Australian multiple-case families. Here we report genome-wide measured 210 peripheral blood samples provided family members using Infinium HumanMethylation450. develop and apply a new statistical method identify based on complex segregation analysis. estimate carrier probabilities...
Pembrolizumab and olaparib have shown single-agent activity in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).To evaluate the efficacy safety of pembrolizumab plus mCRPC.Cohort A phase 1b/2 KEYNOTE-365 study enrolled molecularly unselected, docetaxel-pretreated mCRPC whose disease progressed within 6 mo screening.Pembrolizumab 200 mg intravenously every 3 wk 400-mg capsule or 300-mg tablet orally twice daily.The primary endpoints were safety,...
In JAVELIN Bladder 100, avelumab first-line maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) versus BSC alone in patients with advanced urothelial carcinoma (aUC) without disease progression platinum-containing chemotherapy.To evaluate patient-reported outcomes (PROs) alone.A randomized phase 3 trial (NCT02603432) was conducted 700 locally or metastatic that had not progressed gemcitabine cisplatin carboplatin. PROs were a secondary...
Abstract Purpose: To determine the safety, maximum tolerated dose, and pharmacokinetic-pharmacodynamic profile of a histone deacetylase inhibitor, LAQ824, in patients with advanced malignancy. Patients Methods: LAQ824 was administered i.v. as 3-h infusion on days 1, 2, 3 every 21 days. Western blot assays peripheral blood mononuclear cell lysates tumor biopsies pretherapy posttherapy evaluated target inhibition effects heat shock protein-90 (HSP90) client proteins HSP72. Results: Thirty-nine...